Curated News
By: NewsRamp Editorial Staff
June 30, 2026

HeartBeam Completes Heart Attack Detection Study Enrollment Ahead of Schedule

Discuss on Substack Discuss on Telegram View History of this news story on GitHub
Original Source

TLDR

  • HeartBeam completed ALIGN-ACS study ahead of schedule, potentially accelerating FDA approval for heart attack detection and gaining market edge.
  • The ALIGN-ACS pilot study enrolled 120 patients to compare HeartBeam's 3D ECG against standard 12-lead ECG for heart attack detection.
  • HeartBeam's portable 3D ECG technology aims to enable earlier heart attack detection outside hospitals, improving patient outcomes and saving lives.
  • HeartBeam's cable-free 3D ECG device synthesizes signals into a 12-lead ECG, a novel approach for detecting heart attacks anywhere.

Impact - Why it Matters

This news matters because heart attacks are a leading cause of death worldwide, and current detection methods often require bulky equipment or delayed diagnosis. HeartBeam's 3D ECG technology, if approved for heart attack detection, could enable rapid, portable, and accurate diagnosis outside of clinical settings, potentially saving lives by reducing time to treatment. The accelerated enrollment suggests strong clinical interest and could speed up regulatory approval, bringing this life-saving technology to patients sooner.

Summary

HeartBeam (NASDAQ: BEAT) has announced the completion of patient enrollment ahead of schedule in its ALIGN-ACS pilot study, which evaluates the HeartBeam System for heart attack detection. The study enrolled 120 patients presenting with chest pain at two clinical sites in Belgrade, Serbia. Participants were evaluated using both a standard 12-lead ECG and the company’s innovative 3D ECG technology. Data analysis is now underway, and HeartBeam plans to present the results at a major cardiology conference later this year. This milestone marks a significant step forward in the company’s mission to transform cardiac care.

The results from the ALIGN-ACS study are expected to support discussions with the FDA on the design of a planned U.S. pivotal trial and a future submission to expand the HeartBeam System’s indication beyond arrhythmia assessment to include heart attack detection. Notably, HeartBeam is also evaluating whether completing enrollment ahead of its previously anticipated third-quarter 2026 timeline could support a more accelerated regulatory pathway. This accelerated progress underscores the company’s commitment to bringing its technology to market quickly.

HeartBeam, Inc. is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The company is creating the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is, delivering actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to appropriate care—all outside of a medical facility. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. The company holds over 20 issued patents related to technology enablement. To view the full press release, visit https://ibn.fm/GEYtp.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, HeartBeam Completes Heart Attack Detection Study Enrollment Ahead of Schedule

blockchain registration record for this content.